Over 50 Cell Line-Derived Xenograft (CDX) Models for Cancer Therapy Research

Cell line-derived xenograft (CDX) models are a well established and widely used in vivo option for preclinical drug efficacy testing. Human tumor samples are cultured as cell lines, then inoculated into immunodeficient mice to test anti-tumor compounds. Benefits of CDX models are its cost effectiveness, fast turnaround time and high efficiency of xenotransplantation.

LIDE has a growing bank of over 50 cell line-derived xenograft (CDX) mouse models.

Cancer Cell line Cancer Cell line
Bladder T24, SW780 Glioblastoma U87-MGU251
Colon RKO, HCT-116, LOVO, SW620, COLO 205, HT-29, GP2D, SW480 Esophageal KYSE30
Breast MDA-MB-468, HCC-1954, MDA-MB-231, HCC1806, ZR-75-1, JIMT-1 Cervical HeLa, C-33A
Gastric KATO III, NCI-N87, BGC823, MKN45, N87-Claudin 18.2 Myeloma MOLP-8
Pancreatic MIA PaCa-2, PANC-1, ASPC-1, BXPC-3 Osteoblastoma K7M2
Prostate PC-3, LNCap, Du 145, 22Rv1 Lung NCI-H226, A549,Clau-3, NCI-H1975, SHP-77, NCI-H460, NCI-H2009, NCI-H2122, HCC827, NCI-H292
Kidney A498, 786-O
Embryonic: HEK293-Claudin 18.2
Liver HepG2, Hep-3B, Huh7, SNU-398
Melanoma A375 Ovarian SK-OV-3, OVCAR-3, A2780, PA-1
Epidermoid carcinoma A431 Retinoblastoma WERI-Rb-1Y-79
Leukemia/Lymphoma Raji, NALM6, MV-4-11, K-562, MOLT-4, OCI-LY3,Daudi, Ramos(RA 1) Human oral squamous SCC090
Fibrosarcoma/Rhabdo myosarcoma HT-1080 Total 70

CDX models can also be used in our humanized mouse models for evaluating immunotherapies.

LIDE has a biobank with more than 100 human cancer cell lines, and we receive fresh patient samples everyday due to our RWE study in partnership with hospitals all over China. Many cell lines are drug resistant or contain popular target expression phenotypes.

Cancer Cell line Cancer Cell line
Colon Lovo,HT-29,Colo205,SW48,SW480,SW837,HCT-116,SW620,GP2D,RKO,SK-CO-1,DLD1,Colo 741 Ovarian SK-OV-3, OVCAR-3, A2780, PA-1, ES-2, EFO-21, TOV-21G
Breast MDA-MB-231, MDA-MB-468, HCC-1954,BT474,MDA-MB-157,MDA-MB-453,SK-BR-3, T-47D, MCF7 Pancreatic MIA-Paca-2, Aspc-1, BXPC-3, HPAC, PANC-05.04, PANC-1, SW1990, Panc10.05, Capan 2
Gastric MKN-45, NCI-N87, SNU-16, KATO III, KATO3-T5-BN,BGC823,SNU-5,NUGC4,MKN28, Hep3B, Hs746T Lung A549, CALU-1, H460, DM14, H2009, H1975, H1703, HCC827, H2122, NCI-H226, Calu-3, H1299, H23, H358, SK-LU-1, EBC-1, H1993, H596, NCI-H441
Prostate PC-3 LNCap, Du 145, 22RV1 Osteosarcoma 143B, MG-63, Saos-2, U-2 OS
Melanoma A375, MOLP-8, SK-MEL-5 Esophageal KYSE30, OE19
Liver HepG2, Hep-3B, Huh7, SNU-398, SK-HEP-1 Glioblastoma U87MG, U251, A172, LN-229, U-118 MG
Lymphoma Raji, Daudi, NALM-6, KARPAS-299, MV4-11, OCI-LY3 AML U87MG, U251, A172, LN-229, U-118 MG
Leukemia/MM K562, Jurkat Bladder Cancer 5637
Fibrosarcoma HT-1080 Kidney A498
Epidermoid carcinoma A431 Cervical Hela
    Total 106